Mostrar el registro sencillo del ítem
| dc.contributor.author | Genesca, Eulalia | |
| dc.contributor.author | Morgades, Mireia | |
| dc.contributor.author | González-Gil, Celia | |
| dc.contributor.author | Fuster-Tormo, Francisco | |
| dc.contributor.author | Haferlach, Claudia | |
| dc.contributor.author | Meggendorfer, Manja | |
| dc.contributor.author | Montesinos, Pau | |
| dc.contributor.author | Barba, Pere | |
| dc.contributor.author | Gil, Cristina | |
| dc.contributor.author | Coll, Rosa | |
| dc.contributor.author | Moreno, María-José | |
| dc.contributor.author | Martínez-Carballeira, Daniel | |
| dc.contributor.author | García-Cadenas, Irene | |
| dc.contributor.author | Vives, Susana | |
| dc.contributor.author | R, | |
| dc.date.accessioned | 2025-10-20T14:40:39Z | |
| dc.date.available | 2025-10-20T14:40:39Z | |
| dc.date.issued | 2021-10 | |
| dc.identifier.citation | Genescà E, Morgades M, González-Gil C, Fuster-Tormo F, Haferlach C, Meggendorfer M, et al. Adverse prognostic impact of complex karyotype (¿3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Leukemia Research. octubre de 2021 | |
| dc.identifier.issn | 0145-2126 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/20507 | |
| dc.description.abstract | The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of >3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with >3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corre-sponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying kar-yotypes with >3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), inde-pendently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Addi-tional molecular analyses of patients carrying >3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel tar-geted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients. | |
| dc.language.iso | eng | |
| dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | |
| dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
| dc.subject.mesh | Adolescent | |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Chromosome Aberrations | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Karyotype | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Neoplasm, Residual/diagnosis/genetics | |
| dc.subject.mesh | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis/genetics | |
| dc.subject.mesh | Prognosis | |
| dc.subject.mesh | Young Adult | |
| dc.title | Adverse prognostic impact of complex karyotype (¿3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL) | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 34139642 | |
| dc.relation.publisherversion | https://dx.doi.org/10.1016/j.leukres.2021.106612 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1016/j.leukres.2021.106612 | |
| dc.journal.title | Leukemia Research | |
| dc.identifier.essn | 1873-5835 |